KIF5B-RET fusion molecules and uses thereof

US9884060B2 · kind B2 · utility

Assignee

• Foundation Medicine, Inc. · US

Inventors

• Sean R. Downing · Methuen, US
• Matthew J. Hawryluk · Watertown, US
• Doron Lipson · Cambridge, US
• Alexander N. Parker · Dedham, US
• Philip James Stephens · Lexington, US

Key dates

• Filing date: Feb 17, 2016
• Grant date: Feb 6, 2018
• Expiry date: Feb 17, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel RET fusion molecules and uses are disclosed. In one embodiment, a KIF5B-RET fusion includes an in-frame fusion of an exon of KIF5B (e.g., one or more exons encoding a kinesin motor domain or a fragment thereof) and an exon of RET (e.g., one or more exons encoding a RET tyrosine kinase domain or a fragment thereof). For example, the KIF5B-RET fusion can include an in-frame fusion of at least exon 15 of KIF5B or a fragment thereof (e.g., exons 1-15 of KIF5B or a fragment thereof) with at least exon 12 of RET or a fragment thereof (e.g., exons 12-20 of RET or a fragment thereof).